7,539,602 Shares in Omnicell, Inc. $OMCL Bought by BlackRock Inc.

BlackRock Inc. bought a new position in shares of Omnicell, Inc. (NASDAQ:OMCL) in the second quarter, HoldingsChannel reports. The firm bought 7,539,602 shares of the company’s stock, valued at approximately $313,044,000. BlackRock Inc. owned approximately 0.17% of Omnicell as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of OMCL. Versant Capital Management Inc lifted its stake in Omnicell by 38.7% in the 2nd quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock valued at $44,000 after buying an additional 294 shares in the last quarter. Cerity Partners LLC increased its position in shares of Omnicell by 4.9% in the fourth quarter. Cerity Partners LLC now owns 7,613 shares of the company’s stock worth $345,000 after acquiring an additional 354 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Omnicell by 1.2% in the 2nd quarter. Thrivent Financial for Lutherans now owns 34,445 shares of the company’s stock valued at $1,013,000 after acquiring an additional 424 shares during the period. Legal & General Group Plc raised its stake in shares of Omnicell by 0.3% in the 3rd quarter. Legal & General Group Plc now owns 158,399 shares of the company’s stock valued at $4,823,000 after acquiring an additional 448 shares during the period. Finally, California State Teachers Retirement System lifted its holdings in shares of Omnicell by 1.7% during the 2nd quarter. California State Teachers Retirement System now owns 42,552 shares of the company’s stock valued at $1,251,000 after acquiring an additional 692 shares in the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Stock Performance

Shares of NASDAQ OMCL opened at $33.45 on Thursday. The stock has a market capitalization of $1.52 billion, a P/E ratio of 39.82, a P/E/G ratio of 0.83 and a beta of 0.98. The firm’s 50-day moving average price is $40.04 and its two-hundred day moving average price is $39.40. Omnicell, Inc. has a 52-week low of $29.06 and a 52-week high of $55.00. The company has a quick ratio of 1.43, a current ratio of 1.64 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47. The business had revenue of $312.21 million during the quarter, compared to analyst estimates of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. As a group, sell-side analysts forecast that Omnicell, Inc. will post 1.41 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on OMCL. Weiss Ratings upgraded Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 18th. Piper Sandler reaffirmed an “overweight” rating and set a $45.00 price target (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. Wells Fargo & Company lowered their target price on Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Zacks Research lowered Omnicell from a “hold” rating to a “strong sell” rating in a research note on Friday, August 7th. Finally, Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday, May 10th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Omnicell has a consensus rating of “Moderate Buy” and a consensus price target of $57.86.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.